Home > Insider Trading > Filing (0001140361-18-030192)

Filing Details

Accession Number:: 0001140361-18-030192
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-06-27 18:20:02
Reporting Period:: 2018-06-25

Accepted Time:: 2018-06-27 18:20:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1645666	Kezar Life Sciences Inc.	KZR	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1583977	Cormorant Asset Management, Lp	200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	Yes	No
1599214	Bihua Chen	C/O Cormorant Asset Management, Llc 100 High Street, Suite 1103 Boston MA 02110	Yes	No	Yes	No
1618442	Cormorant Global Healthcare Master Fund, Lp	100 High Street Suite 1105 Boston DC 02110	No	No	Yes	No
1618451	Cormorant Global Healthcare Gp, Llc	100 High Street 1 Federal Street Boston MA 02110	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-06-25	315,488	$0.00	315,488	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-06-25	1,007,421	$0.00	1,322,909	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2018-06-25	250,000	$15.00	1,572,909	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Redeemable Convertible Preferred Stock	Disposition	2018-06-25	315,488	$0.00	315,488	$0.00
Common Stock	Series B Redeemable Convertible Preferred Stock	Disposition	2018-06-25	1,007,421	$0.00	1,007,421	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Shares of Series A Redeemable Convertible Preferred Stock ("Series A Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.
Shares of Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.
Shares reported herein are held by Cormorant Private Healthcare Fund I, LP (the "Fund I"), Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and by a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
The Series A Preferred Stock represented, on an as-converted basis (i) 265,799 shares of Common Stock held by the Master Fund, and (ii) 49,689 shares of Common Stock held by the Account.
The Series B Preferred Stock represented, on an as-converted basis (i) 803,116 shares of Common Stock held by Fund I, (ii) 169,952 shares of Common Stock held by the Master Fund, and (iii) 34,353 shares of Common Stock held by the Account.
Shares reported herein as purchased on June 25, 2018 represent (i) 216,575 shares purchased by the Master Fund, and (ii) 33,425 shares purchased by the Account.